Background: Necrotizing enterocolitis (NEC) is associated with loss of neurons and glial cells in the enteric nervous system (ENS). Our goal was to determine whether enteric neural stem cell (NSC) transplantation, in conjunction with heparin-binding epidermal growth factor-like growth factor (HB-EGF), could protect against experimental NEC. Methods: In vitro, HB-EGF on NSC proliferation and migration, and the effects of receptors utilized by HB-EGF to exert these effects, were determined. In vivo, mouse pups were exposed to experimental NEC and treated with NSC alone, HB-EGF alone, NSC+HB-EGF, or HB-EGF overexpressing NSC. NSC engraftment and differentiation into neurons in the ENS, intestinal injury, intestinal permeability, and intestinal motility were determined. results: HB-EGF promoted NSC proliferation via ErbB-1 receptors and enhanced NSC migration via ErbB-1, ErbB-4, and Nardilysin receptors. HB-EGF significantly enhanced the engraftment of transplanted NSC into the ENS during NEC. NSC transplantation significantly reduced NEC incidence and improved gut barrier function and intestinal motility, and these effects were augmented by simultaneous administration of HB-EGF or by transplantation of HB-EGF overexpressing NSC. conclusion: HB-EGF promotes NSC proliferation and migration. HB-EGF and NSC reduce intestinal injury and improve gut barrier function and intestinal motility in experimental NEC. Combined HB-EGF and NSC transplantation may represent a potential future therapy to prevent NEC.
n ecrotizing enterocolitis (NEC) is the most common cause of gastrointestinal mortality in newborns, typically affecting babies born prematurely with low birth weight. NEC affects ~7% of infants with a birth weight between 500 and 1,500 g. The overall mortality rate of NEC is 20-30% (ref. 1) . Despite intensive research, the incidence and mortality of NEC have remained unchanged over the past six decades.
The enteric nervous system (ENS) is a collection of neurons and supportive glial cells organized in ganglia throughout the gastrointestinal tract (2) . The ENS controls intestinal motility, modulates visceral sensation, and regulates intestinal blood supply and secretion of digestive hormones (3) . In addition, the ENS modulates the proliferation and differentiation of intestinal epithelial cells via the secretion of distinct neuromediators (4) . ENS immaturity in premature babies leads to poor intestinal motility and resultant bacterial overgrowth and translocation, which may increase vulnerability to NEC (5) . We and others have documented ENS abnormalities in the intestines of patients with NEC, suggesting that an immature ENS may predispose premature infants to develop the disease (6) . Furthermore, we have shown that the ENS injury associated with acute clinical NEC persists for months, suggesting that the ENS is restricted in its ability to recover from injury (6) .
Stem cell therapy holds a powerful potential to treat ENS abnormalities by replacing damaged neurons with transplanted cells. Enteric neural stem cells (NSC) may represent an ideal source of stem cells for neurotransplantation since these cells are committed to differentiate into neurons and glial cells after transplantation. It has been reported that transplanted NSC isolated from human neonates can colonize aganglionic gut and differentiate into neurons and glial cells (7) . However, NSC transplantation has limited success due to the low survival rate of the engrafted cells after transplantation (8) .
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) was initially isolated from cultured human macrophages (9) , and later identified as a member of the epidermal growth factor (EGF) family (10) . HB-EGF is a potent mitogen and chemotactic factor, and we have previously demonstrated that enteral administration of HB-EGF protects the intestines from histologic injury (11) , promotes enterocyte migration and proliferation (12) , and preserves intestinal stem cell viability during experimental NEC (13) . We also showed that administration of HB-EGF enhances mesenchymal stem cell engraftment into injured intestine and promotes the efficacy of mesenchymal stem cell transplantation in animal models of NEC (14) and intestinal ischemia/reperfusion injury (15) . We therefore hypothesized that HB-EGF may enhance the effect of NSC transplantation in NEC and augment the therapeutic HB-EGF increased the number of viable NSC in a dosedependent manner, with addition of HB-EGF at 50, 75, or 100 ng/ml leading to significant increases in the number of viable NSC (Figure 1a) . HB-EGF also promoted NSC migration in a dose-dependent manner, with addition of HB-EGF at 25, 50, or 75 ng/ml leading to significant increases in NSC migration (Figure 1b) .
HB-EGF Promotes NSC Viability via ErbB-1 and Promotes NSC Migration via ErbB-1, ErbB-4, and Nardilysin
To determine which receptors are utilized by HB-EGF in promoting NEC viability and migration, we first used RT-PCR to determine the expression of ErbB-1, ErbB-2, ErbB-3, ErbB-4, and Nardilysin in NSC and found that NSC express all of these receptors (Figure 2a) . We then transfected NSC with siRNA to each individual receptor to decrease expression of the receptor. Quantitative real-time PCR confirmed significantly decreased expression of ErbB-1, ErbB-2, ErbB-3, ErbB-4, and Nardilysin mRNA after respective siRNA transfection (Figure 2b) . Transfection with siRNA to ErbB-1 significantly decreased HB-EGF-mediated NSC viability compared with transfection with scrambled siRNA, whereas HB-EGF-mediated NSC viability was not affected by transfection of NSC with siRNA to ErbB-2, ErbB-3, ErbB-4, or Nardilysin, suggesting that the effects of HB-EGF on NSC viability are mediated solely via ErbB-1 (Figure 2c) . We next investigated the effect of these receptors on NSC migration. We found that transfection of NSC with siRNA to ErbB-1, ErbB-4, and Nardilysin significantly decreased HB-EGF-mediated NSC migration compared with scramble siRNA transfection, whereas HB-EGF-mediated NSC migration was not affected by transfection of NSC with siRNA to ErbB-2 or ErbB-3 (Figure 2d) . These results suggest that the effects of HB-EGF on NSC migration are mediated via ErbB-1, ErbB-4, and Nardilysin.
Enterally Administered HB-EGF Increases NSC Proliferation In Vivo
To determine whether HB-EGF promotes the proliferation of engrafted enhanced green fluorescent protein (EGFP)-labeled NSC in vivo, we performed double immunohistochemical staining for EGFP and Ki67 (proliferation cell marker) in intestinal sections from pups exposed to NEC+NSC or to NEC+NSC+HB-EGF. We found that the percentage of cells that express both Ki67 and GFP/total GFP-positive cells was significantly increased in the NEC+NSC+HB-EGF group compared with the NEC+NSC group, indicating that enterally administered HB-EGF increases NSC proliferation in vivo (Figure 3a) .
HB-EGF Enhances the Engraftment of Transplanted NSC Into the ENS During NEC
We next tested the effects of HB-EGF on EGFP-labeled NSC in our experimental NEC model in vivo. We first confirmed that transfection of murine NSC with a human HB-EGF expression plasmid led to significantly increased expression of human HB-EGF mRNA in HB-EGF-transfected Representative crystal violet stained images of migrated NSC trapped in polycarbonate membrane inserts in the presence of (i) no HB-EGF; (ii) HB-EGF 25 ng/ ml; (iii) HB-EGF 50 ng/ml; (iv) HB-EGF 100 ng/ml, with quantification of NSC migration shown in the bar graph. Scale bar = 50 µm. Magnification: ×100. *P < 0.05 vs. no addition. All values represent mean ± SD. HB-EGF, heparin-binding epidermal growth factor-like growth factor; NSC, neural stem cell. 
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Articles NSC compared with scramble-transfected NSC. Double immunofluorescence staining for EGFP and human HB-EGF was performed in intestinal sections from pups exposed to NEC + scramble transfected NSC or NEC+HB-EGF-overexpressing NSC. We confirmed that HB-EGF-overexpressing NSC produced easily detectable HB-EGF protein in vivo (Figure 3b) . Double immunofluorescence staining of intestinal sections was also performed for EGFP and for the pan neuronal cell marker HuC/D (Figure 3c) . Engrafted EGFP-positive cells were distributed (c) Effect of receptor silencing on NSC viability. Black bars, control; white bars, HB-EGF. *P = 0.02. (d) Effect of receptor silencing on HB-EGF-mediated NSC migration. *P < 0.01 vs. scramble siRNA-transfected NSC+HB-EGF (50 ng/ml). The images represent migration of: (e) NSC with no addition; (f) NSC+ HB-EGF (50 ng/ml); (g) scramble siRNA-transfected NSC+HB-EGF (50 ng/ml); (h) ErbB-1 siRNA-transfected NSC+HB-EGF (50 ng/ml); (i) ErbB-2 siRNA transfected NSC+HB-EGF (50 ng/ml); (j) ErbB-3 siRNA-transfected NSC+HB-EGF (50 ng/ml); (k) ErbB-4 siRNA-transfected NSC+HB-EGF (50 ng/ml); (l) Nardilysin siRNA-transfected NSC+HB-EGF (50 ng/ml). Scale bar = 50 µm. Magnification: ×100. All values represent mean ± SD. HB-EGF, heparin-binding epidermal growth factor-like growth factor; NSC, neural stem cell. Articles in the muscularis and mucosa of the recipient intestine, including the submucosal and myenteric plexuses. A subset of EGFP-positive cells were immunoreactive to HuC/D, indicating transplanted NSC that differentiated into mature neurons. Pups exposed to experimental NEC that received NSC i.p. had significantly increased NSC engraftment into the intestines compared with breastfed pups that received NSC i.p., demonstrating that NSC preferentially engraft into NEC-injured intestine rather than intact intestine (Figure 3d) . In pups subjected to NEC, administration of enteral HB-EGF in conjunction with NSC transplantation led to significantly increased NSC engraftment compared with administration of NSC alone. HB-EGF-overexpressing NSC demonstrated similar effects, with increased engraftment into NEC-affected intestine compared with administration of either nontransfected NSC or scramble-transfected NSC.
HB-EGF Promotes Engrafted NSC Differentiation and Protects the ENS From NEC Injury
Significant enteric neuronal loss was found in pups exposed to NEC compared with pups that were breast-fed, confirming ENS injury during NEC (Figure 3e) . Administration of enteral HB-EGF in conjunction with NSC transplantation led to a significant increase in total neurons in the intestine compared with pups subjected to NEC that were treated with NSC alone. Administration of HB-EGF-overexpressing NSC led to significantly increased neurons in the intestine compared with administration of either nontransfected NSC or scrambletransfected NSC. Lastly, we quantified differentiated neurons derived from engrafted NSC (cells double stained for EGFP and HuC/D). Administration of enteral HB-EGF in conjunction with nontransfected NSC led to a significant increase in the number of differentiated neurons derived from engrafted NSC compared with pups treated with nontransfected NSC alone (Figure 3f) . Furthermore, administration of HB-EGFoverexpressing NSC led to a significant increase in the number of differentiated neurons derived from engrafted NSC compared with administration of either nontransfected NSC or scramble-transfected NSC. These results demonstrate that HB-EGF promotes NSC differentiation and protects the ENS from injury during NEC.
HB-EGF and NSC Act Together to Reduce Intestinal Injury During Experimental NEC
Representative images for each intestinal injury grade are shown in Figure 4a . Pups exposed to experimental NEC had a significantly increased incidence of histologic injury compared with breastfed pups (68.8 vs. 0%; P < 0.01; Figure 4b ). Pups exposed to NEC that received NSC alone or enteral HB-EGF alone had a significantly decreased incidence of NEC compared with pups subjected to nontreated NEC (48.7 vs. 68.8%; P = 0.047 and 38.4 vs. 68.8%; P = 0.012). A further decrease in the incidence of NEC was achieved with simultaneous administration of HB-EGF and NSC compared with treatment with NSC alone (25.8 vs. 48.7%; P = 0.043). A significant decrease in the incidence of NEC was also achieved by administration of HB-EGF-overexpressing NSC compared with scrambletransected NSC (25.9 vs. 48.8%; P = 0.048). The efficacy of administration of HB-EGF-overexpressing NSC was equivalent to the efficacy of simultaneous administration of HB-EGF and NSC. Articles Wei et al.
HB-EGF and NSC Act Together to Preserve Gut Barrier Function
Pups that were breastfed or breastfed with administration of NSC had intact gut barrier function with normal intestinal permeability (Figure 5a ). Pups exposed to NEC had significantly increased intestinal permeability compared with pups that were breastfed, indicating gut barrier dysfunction associated with NEC. Pups exposed to NEC that received NSC alone or HB-EGF alone had significantly decreased intestinal permeability compared with pups subjected to nontreated NEC. A further significant decrease in intestinal permeability was achieved by simultaneous administration of HB-EGF and NSC compared with treatment with either NSC alone or with HB-EGF alone. Significantly decreased intestinal permeability was also achieved by administration of HB-EGFoverexpressing NSC compared with nontransfected NSC or scramble-transfected NSC. The efficacy of administration of HB-EGF-overexpressing NSC was equivalent to the efficacy of simultaneous administration of HB-EGF and NSC.
HB-EGF and NSC Act Together to Promote Intestinal Motility
Pups exposed to NEC had significantly decreased intestinal motility compared with breastfed pups as measured by methylene blue dye migration (Figure 6 ). There was increased intestinal motility in pups exposed to NEC that were treated with enteral HB-EGF or scramble transfected NSC compared with pups subjected to nontreated NEC. Pups exposed to NEC that received HB-EGF overexpressing NSC had intestinal motility that was completely restored to normal levels.
DISCUSSION
Recent evidence suggests that an immature ENS may play a role in the pathogenesis of NEC. Furthermore, interventions to prevent ENS damage during NEC are highly desirable. In this study, we have shown that NSC transplantation and HB-EGF can protect the ENS and the intestines from NEC. Enteric NSCs have characteristic self-renewing capabilities and terminally differentiate into neurons and glial cells, providing the potential to rebuild an impaired ENS. NSCs obtained from gut mucosal biopsy specimens in children undergoing endoscopy have been successfully used to generate neurospheres capable of proliferation and differentiation, and which generated ganglion-like structures including neurons and glial cells after transplantation into aganglionic human hindgut (16) . The graft-derived neurons had morphological, neurochemical, and electrophysiological characteristics similar to enteric neurons (17) . However, an inflammatory microenvironment can have significant negative impact on the survival, proliferation, and migration of grafted NSC (8) . Proinflammatory cytokines such as IL-1β and IL-6 suppress neuronal differentiation (18) , potentially diminishing the beneficial effects of engrafted NSC. We have previously demonstrated that HB-EGF significantly reduces intestinal ischemia/ reperfusion injury-induced expression of the proinflammatory cytokines TNF-α, IL-1β, and IL-6 in vivo (19) . We have also shown that HB-EGF protects many cell types including intestinal stem cells from injury (20) and promotes murine ENS development and enteric neural crest cell migration (21) . In our current study, HB-EGF increased the number of viable NSC at least in part by increasing NSC proliferation, but may also act by decreasing NSC apoptosis. HB-EGF also promoted NSC migration. The combined effects of HB-EGF on inflammatory cytokines, NSC proliferaton, and NSC migration may enhance the therapeutic effects of NSC transplantation. cecum. Dye migration was measured as the ratio of migration distance/ total intestinal length. Values represent mean ± SD. n = 6 for each group. *P < 0.01; **P < 0.05. HB-EGF, heparin-binding epidermal growth factorlike growth factor; NEC, necrotizing enterocolitis. Articles Like other members of the EGF family, HB-EGF can interact with the four known EGF receptors (ErbB-1, ErbB-2, ErbB-3, and ErbB-4). In addition, Nardilysin acts as an HB-EGFspecific receptor (22) . The current study demonstrates that administration of HB-EGF promotes NSC proliferation via ErbB-1 and enhances NSC migration via ErbB-1, ErbB-4, and Nardilysin. HB-EGF/ErbB-4 signaling is known to be associated with proper development of neuromere/pharynegeal tissues during cranial neural crest cell migration to the periphery (23) . Nardilysin is a highly specific receptor for HB-EGF (22) , and high levels of Nardilysin transcripts are almost exclusively associated with neural tissues, indicating that Nardilysin may play an important role in neuronal development (24) . Our results confirm that Nardilysin is involved in HB-EGFmediated NSC migration.
Our in vivo data show that administration of HB-EGF increases the numbers of transplanted NSC that engraft into the intestines during NEC, leading to decreased intestinal injury scores and improved gut barrier function. We also confirmed decreased intestinal motility in pups exposed to NEC and increased motility in pups exposed to NEC that were treated with enteral HB-EGF or with HB-EGF-overexpressing NSC. In addition, both HB-EGF and NSC transplantation led to increased numbers of neurons in the intestines of pups with NEC. This suggests that the therapeutic regimens employed can protect enteric neurons from NEC-induced injury and improve neuronal survival and function. Furthermore, some of the engrafted NSCs differentiate into mature neurons in the injured intestine.
To determine whether HB-EGF exerts its therapeutic effects in experimental NEC by acting directly on NSC, we transfected NSC with the HB-EGF gene to directly overexpress the growth factor in these cells. In this manner, we hoped to eliminate its beneficial effects on other cell types in the intestine. We found that transplantation of HB-EGF-overexpressing NSC had similar efficacy to administration of HB-EGF and nontransfected NSC in combination, suggesting that HB-EGF acts directly on NSC in our model by promoting proliferation or possibly by preserving NSC viability via decreased apoptosis and necrosis of the transplanted cells (20) . Although it is impossible to completely rule out the possibility that HB-EGF protects the ENS from injury secondary to its effects in preserving mucosal integrity, previous work from our laboratory also showed that deletion of the HB-EGF gene directly leads to delayed migration of enteric neural crest cells and a dysfunctional ENS (21) , indicating that HB-EGF has a direct effect on enteric neural crest cells and the ENS.
In summary, the results of our study show that HB-EGF promotes NSC viability via ErbB-1 receptors and enhances NSC migration via ErbB-1, ErbB-4, and Nardilysin receptors. HB-EGF enhances the engraftment of transplanted NSC into the ENS and promotes engrafted NSC proliferation and differentiation during experimental NEC in vivo. In addition, HB-EGF and NSC act together to reduce intestinal injury, to improve gut barrier function during NEC, and to restore intestinal motility upon recovery from NEC. Combined HB-EGF and NSC transplantation may represent a potential clinical therapy to prevent NEC in the future.
METHODS

Animal Ethical Statement
The following experimental protocol followed the guidelines for the ethical treatment of experimental animals as approved by the Institutional Animal Care and Use Committee of the Research Institute at Nationwide Children's Hospital (protocol #02205 AR).
NSC Culture
NSCs were harvested from 11.5 day gestational age (E11.5) pan-EGFP mice (Jackson Laboratory, Bar Harbor, ME) and cultured as described (6) . Fetal intestines were dissected and digested in Collagenase/ Dispase (50 µg/ml; Worthington Biochemical, Freehold, NJ) for 1 h. Centrifuged tissue pellets were retrieved and cultured in Dulbecco's Modified Eagle Medium/Ham's Nutrient Mixture F12 (DMEM/ F12; Corning, Manassas, VA) supplemented 1:1 with N 2 supplement (Gibco, Grand Island, NY), with the addition of mouse basic fibroblast growth factor (b-FGF, 20 ng/ml; Sigma-Aldrich, St Louis, MO), mouse EGF (20 ng/ml; Sigma-Aldrich), 15% chicken embryo extract (Gemini, West Sacramento, CA), and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA). NSCs proliferated and grew as free-floating neurospheres, and the suspended neurospheres were collected by harvesting the culture medium. Neurospheres were confirmed to contain >95% NSC as determined by staining with the stem cellspecific marker Nestin.
NSC Transient Transfection
HB-EGF plasmid transfection for overexpression of HB-EGF.
Neurospheres were mechanically dissociated into single cells and transiently transfected with 4 μg of pCMV6-Entry vector carrying full-length human HB-EGF plasmids (Origene, Rockville, MD) or with scrambled DNA control plasmid, using an Amaxa Basic Nucleofector kit (Lonza, Allendale, NJ) and the Amaxa Nucleofactor ІІ apparatus (Lonza). Transfection efficiency was determined by real-time PCR using the following human HB-EGF primers: sense: 5′-CTCTCCCTGCCAAGTCTCAG -3′ and anti-sense: 5′-CTGCATGGAGTAGCACCAGA-3′. Transfected NSCs were incubated in DMEM/F12 medium supplemented with 5% fetal bovine serum for 24 h prior to administration in vivo.
Knockdown of ErbB and Nardilysin Receptor Expression
Neurospheres were mechanically dissociated into single cells and transfected with 200 nmol/l of siRNA designed to knock down mouse ErbB-1, ErbB-2, ErbB-3, ErbB-4 or Nardilysin genes, or with scrambled siRNA (all from Ambion, Carlsbad, CA) using Amaxa Basic Nucleofector kit (Lonza) and the Amaxa Nucleofactor ІІ apparatus (Lonza). siRNA suppression efficiency and plasmid transfection efficiency were determined by real-time PCR as follows. Total RNA from NSC was extracted using RNA STAT-60 (TEL-TEST, Friendswoods, TX) according to the manufacturer's protocol. Aliquots of 1 µg of total RNA were reverse transcribed using SuperScript ІІ Reverse Transcriptase (Invitrogen) and oligo-dT(18)-primers (Invitrogen). RT-PCR amplification was performed in a 25 µl reaction containing 150 ng cDNA, 12.5 µl 2× QuantiTect PCR Master Mix (Qiagen, Valencia, CA), and 1 µl of 10 nmol/l primers (Integrated DNA Technologies, Skokie, IL). The primers used are shown in Table 1 . The real-time PCR was performed using the SYBR Green Master Mix kit and the ABI Prism 7000 Sequence Detection System (Applied Biosystems, Forster City, CA). Glyceraldehyde-3-phosphate dehydrogenase was amplified as an internal control.
NSC Viability Assay
NSCs were seeded as single cells into 96-well plates at a final concentration of 5,000 cells/well in culture medium containing b-FGF, chicken embryo extract, and N 2 supplement. NSCs were cultured for 6 d in the presence of HB-EGF (0-100 ng/ml). Cell prolifera
